New York-based lifesciences investment group Iguana Healthcare Partners filed an amended notice, reporting that the company has raised more than $53.5 million in pooled investment fund interests.
The funding, raised among 20 unnamed investors, will support Iguana’s interests in pharmaceuticals, biotechnology, medical devices, diagnostics, healthcare services and healthcare information technology.
"Our research strategy is bottom-up and stock-by-stock and will focus on innovation and pharmaco-economics as a driver of sales and earnings growth," according to the company’s website. "Global and sector-specific risk will be actively managed with an eye on capital preservation."
The fundraising efforts began Jan. 4, 2010, and is set to expire Aug. 31, 2015, according to an SEC filing.
Rumor: Orscan Tech. plans IPO on Tel Aviv Stock Exchange
An Israeli newspaper cites inside sources with rumors that medical imaging company Orscan Technologies will launch an initial public offering on the Tel Aviv Stock Exchange, the value of which is not yet clear.
Read more
Endologix raises 2013 guidance in strong Q2 growth
Irvine, Calif.-based Endologix raised its 2013 revenue guidance, now expecting $128-$134 million after posting 33% growth in its 2nd quarter. Read more
Medtronic and Urologix rework payment plan
Urologix’s (NSDQ:ULGX) announced that it restructured its payment obligation to medtech titan Medtronic (NYSE:MDT) for the licensing of the Prostiva radiofrequency therapy system. Read more
Philips Healthcare and Radiological sign licensing & distribution contract
Missouri-based Radiologica signed a long-term licensing and distribution contract with healthcare giant Philips Healthcare (NYSE:PHG), who will sell Radiologica’s fullAccess radiation oncology systems. Read more
Analysts’ ups and downs
- Align Technology (NSDQ:ALGN): Robert W. Baird initiates coverage with “outperform” rating, $45 price target
- Haemonetics (NYSE:HAE): Zacks reiterates “outperform” rating, $50.00 price target
- Hanger (NYSE:HGR): Sidoti initiates coverage with “buy” rating
- Mallinckrodt plc (NYSE: MNK): R. F. Lafferty initiates coverage with “sell” rating
- Thoratec (NSDQ:THOR): Leerink Swann reiterates "outperform" rating, lowers price target to $38 from $43
